CD9 and neoplasm: Recently, it has been described that tumour-initiating cells from the genetically engineered KPC PDAC mouse model upregulate the glutamine transporter ASCT2 and promote its localisation in the plasma membrane via the tetraspanin CD9, enhancing glutamine uptake that fuels tumour initiation and growth (Wang VM.